Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$27.88 USD

27.88
18,846,783

-0.21 (-0.75%)

Updated Nov 4, 2024 01:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Eylea, Dupixent Aid Regeneron's (REGN) Q4 Earnings?

by Zacks Equity Research

Regeneron's (REGN) fourth-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.

Best Growth Stocks to Buy for January 31st

by Zacks Equity Research

PFE, TOL, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 31, 2022

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and J&J

by Zacks Equity Research

Pfizer, BioNTech, Moderna and J&J are included in this analyst blog.

Pfizer (PFE) Gets CHMP Recommendation for COVID Pill Paxlovid

by Zacks Equity Research

Pfizer's (PFE) oral COVID-19 drug, Paxlovid, gets recommendation from the CHMP for its authorization in Europe for treating mild-to-moderate COVID-19 in patients at increased risk of hospitalizations.

Merck (MRK) Keytruda Gets EU Nod for Expanded Kidney Cancer Use

by Zacks Equity Research

Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinoma in certain adult patients who are at an increased risk of recurrence, following nephrectomy.

Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.

Kinjel Shah headshot

Pharma Stock Roundup: J&J Q4 Earnings, FDA's Rejection of PFE, MRK Pipeline Drugs

by Kinjel Shah

J&J (JNJ) reports mixed fourth-quarter results. FDA issues CRL to Merck (MRK) and Pfizer's (PFE) pipeline candidates. FDA approves AbbVie's (ABBV) Skyrizi for a second indication.

Best Growth Stocks to Buy for January 28th

by Zacks Equity Research

CROX, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 28, 2022

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks

by Zacks Equity Research

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Pfizer (PFE), BioNTech Begin Omicron-Based COVID-19 Jab Study

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.

Moderna (MRNA) Starts Study for Omicron-Specific Booster Jab

by Zacks Equity Research

Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.

Best Growth Stocks to Buy for January 27th

by Zacks Equity Research

TOL, PFE, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 27, 2022

Moderna's (MRNA) Investors Losing Wealth: What Lies Ahead?

by Zacks Equity Research

Moderna's (MRNA) stock has been on a declining trend since August 2021 after a strong rally since the beginning of 2020.

The Zacks Analyst Blog Highlights: Mastercard Inc., Pfizer Inc. and Citigroup Inc

by Zacks Equity Research

Mastercard Inc., Pfizer Inc. and Citigroup Inc are included in this blog.

The Zacks Analyst Blog Highlights: Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck

by Zacks Equity Research

Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck are included in this blog.

The Zacks Analyst Blog Highlights: Pfizer, Merck, Eli Lilly, Regeneron and Gilead

by Zacks Equity Research

Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.

Pfizer (PFE) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed at $52.54 in the latest trading session, marking a +1.94% move from the prior day.

The Zacks Analyst Blog Highlights: Roche Holding, Pfizer, Baxter International, STMicro and Philips

by Zacks Equity Research

Roche Holding, Pfizer, Baxter International, STMicro and Philips are included in this analyst blog.

Sheraz Mian headshot

Earnings Season Scorecard and Analyst Reports for Mastercard, Pfizer & Citigroup

by Sheraz Mian

Today's Research Daily features a real-time update on the Q4 earnings season and new research reports on 12 major stocks, including Mastercard Incorporated (MA), Pfizer Inc. (PFE), and Citigroup Inc. (C).

Merck's (MRK) Chronic Cough Drug Gets CRL From FDA

by Zacks Equity Research

Merck's (MRK) new drug application for gefapixant to treat refractory chronic cough or unexplained chronic cough fails to secure approval from the FDA. Meanwhile, the drug secures approval in Japan.

Rimmi Singhi headshot

4 Top-Ranked High Earnings Yield Picks to Add to Your Kitty Now

by Rimmi Singhi

Royal Dutch Shell (RDS.A), Goodyear Tire (GT), Pfizer (PFE) and Crocs, Inc. (CROX) could be some attractive bets if you are looking for high earnings yield picks.

FDA Limits Use of Regeneron & Lilly's COVID Antibody Cocktails

by Zacks Equity Research

The FDA modifies EUA for COVID-19 antibody cocktail drugs of Regeneron (REGN) and Lilly (LLY), limiting their use to treat individuals with COVID-19 infection from non-Omicron variants.

J&J (JNJ) Q4 Earnings Beat Estimates by a Penny, Sales Miss

by Zacks Equity Research

J&J (JNJ) reports mixed fourth-quarter results. It beats estimates for earnings but misses the same for sales.

    Large Cap Pharma, Biotech Stocks Down on Regulatory Updates

    by Zacks Equity Research

    Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.

    Best Growth Stocks to Buy for January 25th

    by Zacks Equity Research

    CROX, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 25, 2022